Evidence map›Paper›PMID 17508724›Full record

ArticleBiochemistry2007

Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease.

Jianhui Zhu, Betsy T Kren, Chang Won Park, Rasim Bilgim, Phillip Y-P Wong, Clifford J Steer

Abstract read
In one paragraph

Article in Biochemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.BioEssays : news and reviews in molecular, cellular and developmental biology · 2010
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jianhui ZhuDepartment of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Betsy T Kren
Chang Won Park
Rasim Bilgim
Phillip Y-P Wong
Clifford J Steer
University of Minnesota Medical Center · US

Funding

VASCULAR PATHOBIOLOGY OF SICKLE CELL DISEASEP01HL055552 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HEBBEL, ROBERT P · 1995 to 2011
$17.3M
THERAPY FOR HYPERAMMONEMIA WITH GENETICALLY ENGINEERED BACTERIAP01HD032652 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI WHITLEY, CHESTER B. · 1995 to 2016
$14.5M
NHLBI NIH HHS P01 HL055552NHLBI NIH HHS P01 HL55552NICHD NIH HHS P01 HD032652
6 · The paper itself

Abstract

Sickle cell disease (SCD) results predominately from a single monogenic mutation that affects thousands of individuals worldwide. Gene therapy approaches have focused on using viral vectors to transfer wild-type beta- or gamma-globin transgenes into hematopoietic stem cells for long-term expression of the recombinant globins. In this study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transposon (Tn) to insert a wild-type beta-globin expression cassette into the human genome for sustained expression of beta-globin. We initially constructed a beta-globin expression vector composed of the hybrid cytomegalovirus (CMV) enhancer chicken beta-actin promoter (CAGGS) and full-length beta-globin cDNA, as well as truncated forms lacking either the 3' or 3' and 5' untranslated regions (UTRs), to optimize expression of beta-globin. Beta-globin with its 5' UTR was efficiently expressed from its cDNA in K-562 cells induced with hemin. However, expression was constitutive and not erythroid-specific. We then constructed cis SB-Tn-beta-globin plasmids using a minimal beta-globin gene driven by hybrid promoter IHK (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, ankyrin-1 promoter), IHbetap (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, beta-globin promoter), or HS3betap (HS3 core element from human betaLCR, beta-globin promoter) to establish erythroid-specific expression of beta-globin. Stable genomic insertion of the minimal gene and expression of the beta-globin transgene for >5 months at a level comparable to that of the endogenous gamma-globin gene were achieved using a SB-Tn beta-globin cis construct. Interestingly, erythroid-specific expression of beta-globin driven by IHK was regulated primarily at the translational level, in contrast to post-transcriptional regulation in non-erythroid cells. The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferring stable, persistent erythroid-specific expression of beta-globin.

Indexed as

Anemia, Sickle CellDNA, ComplementaryDNA PrimersErythrocytesGlobinsHumansK562 CellsPromoter Regions, GeneticRecombinant ProteinsReverse Transcriptase Polymerase Chain ReactionRNATransposasesDNA, ComplementaryDNA PrimersGlobinsRecombinant ProteinsRNAsleeping beauty transposase, humanTransposases

Identifiers

PMID17508724
PMCPMC3893920
OpenAlexW2312626884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.